BerGenBio

Pre-Annual General Meeting Information • Nov 18, 2020

BerGenBio ASA: Notice of Extraordinary General Meeting

BerGenBio ASA: Notice of Extraordinary General Meeting

Bergen, Norway, 18 November 2020 – Notice is hereby given that an Extraordinary

General Meeting in BerGenBio ASA will be held virtually on 9 December 2020 at

16:00 hours (CET).

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and is available

at https://www.bergenbio.com/investors/general-

meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

All shareholders are encouraged to exercise their shareholder rights, either

through advance electronically voting through VPS Investor Services, by using

the enclosed proxy form to provide proxy to the Chairman Sveinung Hole (or the

person he appoints), or to attend the general meeting virtually.

Virtual attendance, advance vote or proxy for the Extraordinary General Meeting

can be registered through the company’s website or VPS Investor Service. All

registered shareholders will receive a reference number and a pin code required

for registration through the company’s website. Reference number and pin code

will be received either by VPS Investor Service or by post depending if the

shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS to save

environment impact.

-Ends-

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on

developing transformative drugs targeting AXL as a potential cornerstone of

therapy for aggressive diseases, including immune-evasive, therapy resistant

cancers and infectious diseases. The company's proprietary lead candidate,

bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad

Phase II oncology clinical development programme focused on combination and

single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class

functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I

clinical testing. In parallel, BerGenBio is developing a companion diagnostic

test to identify patient populations most likely to benefit from bemcentinib:

this is expected to facilitate more efficient registration trials supporting a

precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For

more information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.